Mariner Wealth Advisors Raised Its Pfizer (PFE) Stake; Css Cut Biomarin Pharmaceutical (Put) (BMRN) Stake By $934,500

May 24, 2018 - By Natalie Daughtry

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Logo

Mariner Wealth Advisors Llc increased Pfizer Inc (PFE) stake by 21.79% reported in 2017Q4 SEC filing. Mariner Wealth Advisors Llc acquired 52,655 shares as Pfizer Inc (PFE)’s stock declined 3.13%. The Mariner Wealth Advisors Llc holds 294,292 shares with $10.66 million value, up from 241,637 last quarter. Pfizer Inc now has $210.35 billion valuation. The stock decreased 0.03% or $0.01 during the last trading session, reaching $35.96. About 9.38M shares traded. Pfizer Inc. (NYSE:PFE) has risen 2.43% since May 24, 2017 and is uptrending. It has underperformed by 9.12% the S&P500.

Css Llc decreased Biomarin Pharmaceutical Inc (Put) (BMRN) stake by 75% reported in 2017Q4 SEC filing. Css Llc sold 10,500 shares as Biomarin Pharmaceutical Inc (Put) (BMRN)’s stock declined 13.73%. The Css Llc holds 3,500 shares with $312,000 value, down from 14,000 last quarter. Biomarin Pharmaceutical Inc (Put) now has $15.60 billion valuation. The stock decreased 0.19% or $0.17 during the last trading session, reaching $88.29. About 552,652 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has declined 11.55% since May 24, 2017 and is downtrending. It has underperformed by 23.10% the S&P500.

Investors sentiment increased to 1.21 in 2017 Q4. Its up 0.08, from 1.13 in 2017Q3. It improved, as 37 investors sold BMRN shares while 112 reduced holdings. 51 funds opened positions while 130 raised stakes. 172.01 million shares or 0.29% more from 171.51 million shares in 2017Q3 were reported. Invesco Limited holds 4.51M shares. Shelton Mngmt holds 0.07% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) or 12,217 shares. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Investment Mgmt has invested 0.08% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Ithaka Lc owns 13 shares or 0.96% of their US portfolio. Brown Advisory, Maryland-based fund reported 7,492 shares. Jgp Gestao De Recursos Ltda reported 0.74% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Altrinsic Global Llc stated it has 56,168 shares. Sivik Global Limited Company holds 2.48% or 75,000 shares. Ls Invest Advsrs Ltd Company accumulated 0.01% or 1,451 shares. State Of Alaska Department Of Revenue holds 0.04% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 18,691 shares. Benjamin F Edwards & has 27 shares for 0% of their portfolio. Creative Planning reported 6,192 shares stake. California State Teachers Retirement System stated it has 0.05% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Japan-based Nomura Asset Mgmt Limited has invested 0.11% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Sun Life Financial Incorporated accumulated 0% or 500 shares.

Css Llc increased Tesla Inc (Put) (NASDAQ:TSLA) stake by 167,112 shares to 170,267 valued at $53.01 million in 2017Q4. It also upped Origo Acquisition Corp stake by 34,588 shares and now owns 47,851 shares. Live Nation Entertainment In (Prn) was raised too.

Analysts await BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to report earnings on August, 1. They expect $-0.05 earnings per share, 0.00% or $0.00 from last year’s $-0.05 per share. After $-0.08 actual earnings per share reported by BioMarin Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts -37.50% EPS growth.

Among 28 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 22 have Buy rating, 0 Sell and 6 Hold. Therefore 79% are positive. BioMarin Pharmaceutical had 94 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Perform” rating by Oppenheimer given on Wednesday, November 18. As per Friday, February 23, the company rating was maintained by Stifel Nicolaus. Stifel Nicolaus maintained it with “Buy” rating and $107.0 target in Wednesday, October 18 report. Raymond James initiated BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Tuesday, September 1 with “Outperform” rating. The stock has “Buy” rating by BMO Capital Markets on Friday, July 21. The firm has “Outperform” rating by Credit Suisse given on Monday, January 23. The firm earned “Neutral” rating on Tuesday, August 25 by Wedbush. RBC Capital Markets maintained it with “Buy” rating and $145 target in Monday, August 24 report. Stifel Nicolaus maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rating on Thursday, August 3. Stifel Nicolaus has “Buy” rating and $10700 target. As per Tuesday, July 11, the company rating was maintained by J.P. Morgan.

More notable recent BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) news were published by: Bizjournals.com which released: “Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics ‘gaming’ list” on May 17, 2018, also Seekingalpha.com with their article: “BioMarin’s valoctocogene roxaparvovec shows long-term treatment effect in hemophilia A study” published on May 22, 2018, Streetinsider.com published: “BioMarin Pharma (BMRN) Should Not Be Selling Off on Heme Data – Citi” on May 22, 2018. More interesting news about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were released by: Streetinsider.com and their article: “Viking Global’s 13F Shows New Stakes in Alibaba (BABA), BioMarin (BMRN) and Western Digital (WDC), Increase in …” published on May 15, 2018 as well as Fool.com‘s news article titled: “A Big Decision Is Fast-Approaching for This Rare-Disease Drugmaker” with publication date: May 23, 2018.

Since December 14, 2017, it had 0 buys, and 26 insider sales for $25.15 million activity. 2,450 shares valued at $219,275 were sold by Mueller Brian on Monday, April 30. Ajer Jeffrey Robert sold $122,484 worth of stock. BIENAIME JEAN JACQUES had sold 10,000 shares worth $836,458. FUCHS HENRY J also sold $1.34 million worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares. Davis George Eric had sold 3,350 shares worth $272,523 on Friday, March 23. LAWLIS V BRYAN also sold $333,150 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares. HERON ELAINE J had sold 800 shares worth $71,116.

Investors sentiment increased to 1.06 in 2017 Q4. Its up 0.10, from 0.96 in 2017Q3. It improved, as 51 investors sold PFE shares while 675 reduced holdings. 134 funds opened positions while 632 raised stakes. 4.07 billion shares or 0.28% more from 4.06 billion shares in 2017Q3 were reported. Virtus Inv Advisers invested in 0.1% or 123,350 shares. Ls Inv Advisors Limited Liability Company stated it has 0.93% in Pfizer Inc. (NYSE:PFE). Chesapeake Asset Mngmt Limited Liability Corp has invested 0.34% in Pfizer Inc. (NYSE:PFE). 187,384 are held by Arrowgrass Ptnrs (Us) Ltd Partnership. Gillespie Robinson And Grimm has invested 0.06% in Pfizer Inc. (NYSE:PFE). Schafer Cullen Mngmt Inc reported 1.66% stake. Texas-based Patriot Wealth Mgmt has invested 1.17% in Pfizer Inc. (NYSE:PFE). Northeast Investment Mngmt reported 150,956 shares. Stelac Advisory Service Ltd reported 2,874 shares. Moreover, Alpha Cubed Investments Lc has 0.13% invested in Pfizer Inc. (NYSE:PFE). Prentiss Smith And has invested 0.26% in Pfizer Inc. (NYSE:PFE). 317,300 are owned by Hennessy Advisors Inc. Iberiabank invested in 0.97% or 171,194 shares. Metropolitan Life Insurance Com Ny holds 0.44% of its portfolio in Pfizer Inc. (NYSE:PFE) for 914,500 shares. The Missouri-based Shelter Mutual has invested 2.59% in Pfizer Inc. (NYSE:PFE).

Among 22 analysts covering Pfizer (NYSE:PFE), 9 have Buy rating, 1 Sell and 12 Hold. Therefore 41% are positive. Pfizer had 79 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by SunTrust on Monday, October 16 with “Hold”. The firm has “Hold” rating given on Sunday, January 28 by SunTrust. As per Wednesday, April 6, the company rating was initiated by Societe Generale. The company was maintained on Monday, October 16 by Jefferies. The stock has “Hold” rating by Argus Research on Wednesday, November 2. Piper Jaffray maintained the shares of PFE in report on Friday, August 28 with “Overweight” rating. The stock of Pfizer Inc. (NYSE:PFE) earned “Buy” rating by Jefferies on Monday, June 20. The stock has “Buy” rating by Argus Research on Tuesday, November 3. On Wednesday, January 31 the stock rating was maintained by Morgan Stanley with “Overweight”. The rating was maintained by Piper Jaffray on Thursday, September 14 with “Buy”.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Streetinsider.com which released: “Pfizer (PFE) Says FDA Granted Breakthrough Therapy Designation for Tafamidis for Treatment of Patients with …” on May 23, 2018, also Finance.Yahoo.com with their article: “3 Top Biosimilars that Will Lift Pfizer Inc. Stock Even More” published on May 24, 2018, 247Wallst.com published: “How Much Pfizer Earnings Depend on a Few Brands” on May 01, 2018. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: 247Wallst.com and their article: “What to Look For in the Merck and Pfizer Reports Tuesday Morning” published on April 30, 2018 as well as Seekingalpha.com‘s news article titled: “Pfizer: Buy This Dip?” with publication date: May 03, 2018.

Pfizer Inc. (NYSE:PFE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: